GlassScriptPhysician profile
Rafael Garcia
NPI 1700224896
$9,047.62
in general payments reported to CMS, 2019-2025
23 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $534 · 2021: $32.41 · 2022: $1,697 · 2023: $1,821 · 2024: $1,451 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,685.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,719.73 | 2022-2025 | |
| Alkermes, INC. | $1,080.45 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $960.37 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $896.18 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $881.60 | 2022-2025 | Rexulti, Vyepti |
| Janssen Pharmaceuticals, INC | $478.33 | 2019-2025 | Invega Sustenna, Invega, Invega Trinza |
| Almatica Pharma LLC | $354.02 | 2021-2024 | Loreev Xr, Sertraline Hcl, Venlafaxine |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $351.08 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $312.65 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $312.17 | 2019-2024 | Austedo Xr, Uzedy |
| Indivior INC. | $306.79 | 2019-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $268.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $266.34 | 2019-2023 | Trintellix |
| Allergan, INC. | $258.98 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $194.09 | 2019-2025 | Fanapt, Hetlioz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $122.85 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $111.71 | 2019 | |
| Acadia Pharmaceuticals INC | $45.50 | 2023 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $43.52 | 2019 | |
| Merck Sharp & Dohme LLC | $29.62 | 2022-2023 | Belsomra |
| Janssen Biotech, INC. | $23.39 | 2023 | |
| Bausch Health US, LLC | $15.23 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.64 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.